👨 Testosterone Polycythemia Monitoring Simulator

Testosterone Stimulating Erythropoiesis

Placeholder: testosterone raises EPO and marrow RBC production.

• +20–40%: EPO stimulation (Placeholder short note)
• Weeks: Marrow response (Placeholder short note)
• Increased: Iron utilization (Placeholder short note)
• ~45%: Baseline hct (Placeholder short note)

Mechanism of stimulation

Placeholder: testosterone increases erythropoietin and suppresses hepcidin.

Rising Hematocrit and Blood Viscosity

Placeholder: hematocrit and viscosity climb progressively on therapy.

• 3–5 pts: Typical rise (Placeholder short note)
• 3–12 mo: Onset (Placeholder short note)
• Nonlinear: Viscosity effect (Placeholder short note)
• ~12 mo: Plateau (Placeholder short note)

Viscosity dynamics

Placeholder: viscosity rises steeply once hematocrit exceeds normal range.

Thrombotic Risk Threshold (Hct > 54%)

Placeholder: hematocrit above 54% sharply raises clot risk.

• 54%: Risk threshold (Placeholder short note)
• 50–54%: Action level (Placeholder short note)
• Elevated: Stroke/VTE risk (Placeholder short note)
• Endocrine Society: Guideline basis (Placeholder short note)

Why 54% matters

Placeholder: this threshold marks a steep rise in thrombosis risk.

Monitoring Schedule During Therapy

Placeholder: scheduled hematocrit checks catch rises early.

• Pre-therapy: Baseline check (Placeholder short note)
• 3, 6, 12 mo: Follow-up (Placeholder short note)
• Annual: Ongoing (Placeholder short note)
• CBC/Hct: Test used (Placeholder short note)

Recommended cadence

Placeholder: check hematocrit at 3, 6, and 12 months, then yearly.

Dose Reduction or Phlebotomy Response

Placeholder: lowering dose or phlebotomy brings hematocrit back down.

• ~500 mL: Phlebotomy volume (Placeholder short note)
• ~25–50%: Dose cut (Placeholder short note)
• 4–6 wk: Recheck interval (Placeholder short note)
• <50%: Target hct (Placeholder short note)

Corrective options

Placeholder: phlebotomy or dose reduction restores safe hematocrit.

Placeholder: combined monitoring and response keeps therapy safe.